Bausch Hopes B+L Spin-Out Will 'Unlock' The Value Of Eye-Care Business
Executive Summary
Bausch Health is paying down its debt with a $630m IPO for its Bausch + Lomb eyecare product business.
You may also be interested in...
Samsara Vision Advances Tiny ‘Telescope’ For Macular Degeneration As It Ponders IPO Options
The CONCERTO trial will evaluate the company’s SING IMT, an upgrade of its 12-year-old WA IMT device, in up to 100 people in the US with age-related macular degeneration.
Independence Arrives For Bausch + Lomb Through IPO Priced Lower Than Forecast
Bausch Health shopped Bausch + Lomb IPO at share price between $21 and $24. In trading of nearly 14.4m shares on New York exchange, Bausch + Lomb’s share price stayed above opening $18.50 and reached $20.07 before closing at $20, up 11.11%.
Bausch Health’s 2022 Growth Led By Business With Separation Coming As Soon As One Month
Canadian firm reports Bausch + Lomb full-year and fourth-quarter revenue growth earnings as preparations continue to divest the business. Consumer health led Bausch + Lomb’s segments.